Bacterial Vaginosis : Antibiotics vs Probiotics
Not Applicable
- Conditions
- Health Condition 1: N89- Other noninflammatory disorders ofvaginaHealth Condition 2: N898- Other specified noninflammatory disorders of vaginaHealth Condition 3: N898- Other specified noninflammatory disorders of vagina
- Registration Number
- CTRI/2021/09/036434
- Lead Sponsor
- Dr Baljinder Kaur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Healthy subjects - Women visiting the Gynecology OPD for regular health checkup or seeking contraception.
2. Bacterial Vaginosis - Women visiting the Gynecology OPD having discharge, abdominal pain,and infertility.
Exclusion Criteria
Healthy Subjects - Women who are pregnant, menstruating, handicapped or on any other medication for any other illness.
Bacterial Vaginosis - Women who are pregnant, menstruating, handicapped or on any other medication for any other illness.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Metagenomics will reveal identity of pathogens associated with Baterial Vaginosis. Biological diversities (alpha and beta diversities)of Bacterial Vaginosis infected human vaginal ecosystem w.r.t. healthy vagina will be revealed to predict actual pathophysiology of Bacterial Vaginosis. <br/ ><br>2. Comparative assessment of efficacy of antibiotics vs. probiotics to control Bacterial Vaginosis in humans.Timepoint: year1-comparitive metagenomic profiling of the healthy human and Bacterial Vaginosis infected vaginal microflora; Year2-Selection of best antibiotc and probiotic formulations for proposing best anti bacterial vaginosis therapy;year3-Comparitive vaginal metagenomic profiling of antibiotic treated and probiotic treated bacterial vaginosis patients for investigating treatment efficiencies.
- Secondary Outcome Measures
Name Time Method Proposing probiotic solutions for drug resistant Bacterial Vaginosis pathogens.Timepoint: Metagenomic profiling of healthy humans-1-6months; metagenomic profiling of Bacterial Vaginosis patients -7-12months; selection of best antibiotic and probiotic formulation -13-24months; metagenomic profiling of antibiotic and probiotic treated Bacterial vaginosis patient-24-36months